New Blue Health utilizes a structured, uncompromising methodology to evaluate and grade clinical evidence. Our goal is to provide patients with a clear, objective understanding of the "strength" and maturity of the science behind various longevity and metabolic pathways. We do not engage in "cherry-picking" data to support a specific outcome; instead, we present the full landscape of current research, including where data may be conflicting, limited, or strictly mechanistic.
Our methodology is inspired by established clinical grading systems like GRADE, but adapted for the specific, rapidly evolving realities of peptide therapy and longevity medicine. We believe that by being radically transparent about how we evaluate science, we empower our patients to make more informed, safer decisions alongside their licensed clinicians.
The New Blue Evidence Hierarchy
- Level 1: Highest-Confidence Regulatory Evidence: Official FDA-approved drug labels and large-scale (Phase III) Randomized Controlled Trials (RCTs) with established safety profiles and long-term outcome data in human populations.
- Level 2: Peer-Reviewed Clinical Data: Smaller-scale RCTs, longitudinal observational studies, and meta-analyses published in reputable, high-impact medical journals.
- Level 3: Mechanistic & Pre-clinical Research: In-vitro or animal model studies that describe a molecule's potential mechanism of action. This evidence is considered exploratory.
Our Transparency Commitment
Evidence quality varies significantly by molecule. We explicitly state uncertainty where it exists. If a molecule's primary discussed benefit is based on mechanistic theory rather than established human outcome data, we prioritize that distinction for our patients.
Our "Evidence Quality" rating on individual molecule evidence hubs provides a quick, clear reference for the maturity of the underlying science. We also discuss the nuances of the studies themselves, noting factors like blinding, control groups, and potential sources of bias.
Evidence quality varies by molecule, population, and endpoint. Where data is limited or mixed, uncertainty is stated directly.
This content is educational and does not replace individualized medical advice. Treatment decisions should be made with a licensed clinician based on personal history, risk profile, and appropriate monitoring.
Medical review & editorial standards
This page is educational content from the New Blue Health Clinical Content Team. It is reviewed under the New Blue Health Medical Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.